Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response | Zendy

Michael J. Palmowski | Zendy; Luciene Lopes | Zendy; Yasuhiro Ikeda | Zendy; Mariolina Salio | Zendy; Vincenzo Cerundolo | Zendy; Mary Collins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response

Author(s) -

Michael J. Palmowski,

Luciene Lopes,

Yasuhiro Ikeda,

Mariolina Salio,

Vincenzo Cerundolo,

Mary Collins

Publication year - 2004

Publication title -

the journal of immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.737

H-Index - 372

eISSN - 1550-6606

pISSN - 0022-1767

DOI - 10.4049/jimmunol.172.3.1582

Subject(s) - ctl* , cytotoxic t cell , viral vector , immunogenicity , biology , transduction (biophysics) , in vivo , ex vivo , virology , cd8 , transgene , microbiology and biotechnology , in vitro , immunology , antigen , recombinant dna , gene , genetics , biochemistry

Lentiviral vectors can efficiently transduce a variety of nondividing cells, including APCs. We assessed the immunogenicity of a lentiviral vector encoding the melanoma Ag NY-ESO-1 in HLA-A2 transgenic mice. Direct i.v. injection of NY-ESO-1 lentivirus induced NY-ESO-1(157-165)-specific CD8(+) cells, detected ex vivo with an A2/H-2K(b) chimeric class I tetramer. These NY-ESO-1(157-165)-specific CD8(+) cells could be expanded by boosting with an NY-ESO-1 vaccinia virus and could kill NY-ESO-1(157-165) peptide-pulsed targets in vivo. Such direct lentiviral vector injection was similar in potency to the injection of in vitro-transduced dendritic cells (DC). In addition, human monocyte-derived DC transduced by the NY-ESO-1 lentivirus stimulated an NY-ESO-1(157-165)-specific specific CTL clone. These data suggest that direct lentiviral transduction of DC in vivo might provide a powerful immunotherapeutic strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research